Safety and Effectiveness of Ruxolitinib in Real-World Patients with Myelofibrosis: A 2-Year Observational Study from Taiwan

Safety and Effectiveness of Ruxolitinib in Real-World Patients with Myelofibrosis: A 2-Year Observational Study from Taiwan

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2022-11, Vol.140 (Supplement 1), p.9709-9710
Hauptverfasser: Kuo, Ming-Chung, Lin, Chien-Chin, Lin, Hsuan-Yu, Gau, Jyh-Pyng, Wang, Ming-Chung, Chang, Ming-Chih, Chen, Tsung-Chih, Yeh, Shih-Peng, Chen, Yeu-Chin, Huang, Cih-En, Chiang, I-Ju, Chung, Chu-Han, Lee, Yee-Ming, Ku, Fan-Chen, Chang, Cheng-Shyong
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 9710
container_issue Supplement 1
container_start_page 9709
container_title Blood
container_volume 140
creator Kuo, Ming-Chung
Lin, Chien-Chin
Lin, Hsuan-Yu
Gau, Jyh-Pyng
Wang, Ming-Chung
Chang, Ming-Chih
Chen, Tsung-Chih
Yeh, Shih-Peng
Chen, Yeu-Chin
Huang, Cih-En
Chiang, I-Ju
Chung, Chu-Han
Lee, Yee-Ming
Ku, Fan-Chen
Chang, Cheng-Shyong
description
doi_str_mv 10.1182/blood-2022-156146
format Article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_156146</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497122059249</els_id><sourcerecordid>S0006497122059249</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1856-654e3dca997c57de5571c9aa3a41607e5d2f6d50a569be73a4c202d5cac5feff3</originalsourceid><addsrcrecordid>eNp9kN1KAzEQRoMoWKsP4F1eIJpkN9muXpVSf6BSaSviVcgmE4xsN5JsWxdf3q312quBYc7HNwehS0avGBvx66oOwRJOOSdMSJbLIzRggo8IpZweowGlVJK8LNgpOkvpg1KWZ1wM0PdSO2g7rBuLp86Baf0WGkgJB4cXm69Q-9Y3vsK-wQvQNXkNsbb4WbcemjbhnW_f8VMHdXC-iiH5dIPHmJM30BHPqwRx25-GRtd42W5sh10Ma7zSfqebc3TidJ3g4m8O0cvddDV5ILP5_eNkPCOGjYQkUuSQWaPLsjCisCBEwUypdaZzJmkBwnInraBayLKCol-b3oMVRhvhwLlsiNgh1_QFUwSnPqNf69gpRtXenvq1p_b21MFez9weGOiLbT1ElUz_sQHrYy9J2eD_oX8Alrp6Bg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Safety and Effectiveness of Ruxolitinib in Real-World Patients with Myelofibrosis: A 2-Year Observational Study from Taiwan</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Kuo, Ming-Chung ; Lin, Chien-Chin ; Lin, Hsuan-Yu ; Gau, Jyh-Pyng ; Wang, Ming-Chung ; Chang, Ming-Chih ; Chen, Tsung-Chih ; Yeh, Shih-Peng ; Chen, Yeu-Chin ; Huang, Cih-En ; Chiang, I-Ju ; Chung, Chu-Han ; Lee, Yee-Ming ; Ku, Fan-Chen ; Chang, Cheng-Shyong</creator><creatorcontrib>Kuo, Ming-Chung ; Lin, Chien-Chin ; Lin, Hsuan-Yu ; Gau, Jyh-Pyng ; Wang, Ming-Chung ; Chang, Ming-Chih ; Chen, Tsung-Chih ; Yeh, Shih-Peng ; Chen, Yeu-Chin ; Huang, Cih-En ; Chiang, I-Ju ; Chung, Chu-Han ; Lee, Yee-Ming ; Ku, Fan-Chen ; Chang, Cheng-Shyong</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-156146</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.9709-9710</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1856-654e3dca997c57de5571c9aa3a41607e5d2f6d50a569be73a4c202d5cac5feff3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Kuo, Ming-Chung</creatorcontrib><creatorcontrib>Lin, Chien-Chin</creatorcontrib><creatorcontrib>Lin, Hsuan-Yu</creatorcontrib><creatorcontrib>Gau, Jyh-Pyng</creatorcontrib><creatorcontrib>Wang, Ming-Chung</creatorcontrib><creatorcontrib>Chang, Ming-Chih</creatorcontrib><creatorcontrib>Chen, Tsung-Chih</creatorcontrib><creatorcontrib>Yeh, Shih-Peng</creatorcontrib><creatorcontrib>Chen, Yeu-Chin</creatorcontrib><creatorcontrib>Huang, Cih-En</creatorcontrib><creatorcontrib>Chiang, I-Ju</creatorcontrib><creatorcontrib>Chung, Chu-Han</creatorcontrib><creatorcontrib>Lee, Yee-Ming</creatorcontrib><creatorcontrib>Ku, Fan-Chen</creatorcontrib><creatorcontrib>Chang, Cheng-Shyong</creatorcontrib><title>Safety and Effectiveness of Ruxolitinib in Real-World Patients with Myelofibrosis: A 2-Year Observational Study from Taiwan</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kN1KAzEQRoMoWKsP4F1eIJpkN9muXpVSf6BSaSviVcgmE4xsN5JsWxdf3q312quBYc7HNwehS0avGBvx66oOwRJOOSdMSJbLIzRggo8IpZweowGlVJK8LNgpOkvpg1KWZ1wM0PdSO2g7rBuLp86Baf0WGkgJB4cXm69Q-9Y3vsK-wQvQNXkNsbb4WbcemjbhnW_f8VMHdXC-iiH5dIPHmJM30BHPqwRx25-GRtd42W5sh10Ma7zSfqebc3TidJ3g4m8O0cvddDV5ILP5_eNkPCOGjYQkUuSQWaPLsjCisCBEwUypdaZzJmkBwnInraBayLKCol-b3oMVRhvhwLlsiNgh1_QFUwSnPqNf69gpRtXenvq1p_b21MFez9weGOiLbT1ElUz_sQHrYy9J2eD_oX8Alrp6Bg</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Kuo, Ming-Chung</creator><creator>Lin, Chien-Chin</creator><creator>Lin, Hsuan-Yu</creator><creator>Gau, Jyh-Pyng</creator><creator>Wang, Ming-Chung</creator><creator>Chang, Ming-Chih</creator><creator>Chen, Tsung-Chih</creator><creator>Yeh, Shih-Peng</creator><creator>Chen, Yeu-Chin</creator><creator>Huang, Cih-En</creator><creator>Chiang, I-Ju</creator><creator>Chung, Chu-Han</creator><creator>Lee, Yee-Ming</creator><creator>Ku, Fan-Chen</creator><creator>Chang, Cheng-Shyong</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>Safety and Effectiveness of Ruxolitinib in Real-World Patients with Myelofibrosis: A 2-Year Observational Study from Taiwan</title><author>Kuo, Ming-Chung ; Lin, Chien-Chin ; Lin, Hsuan-Yu ; Gau, Jyh-Pyng ; Wang, Ming-Chung ; Chang, Ming-Chih ; Chen, Tsung-Chih ; Yeh, Shih-Peng ; Chen, Yeu-Chin ; Huang, Cih-En ; Chiang, I-Ju ; Chung, Chu-Han ; Lee, Yee-Ming ; Ku, Fan-Chen ; Chang, Cheng-Shyong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1856-654e3dca997c57de5571c9aa3a41607e5d2f6d50a569be73a4c202d5cac5feff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kuo, Ming-Chung</creatorcontrib><creatorcontrib>Lin, Chien-Chin</creatorcontrib><creatorcontrib>Lin, Hsuan-Yu</creatorcontrib><creatorcontrib>Gau, Jyh-Pyng</creatorcontrib><creatorcontrib>Wang, Ming-Chung</creatorcontrib><creatorcontrib>Chang, Ming-Chih</creatorcontrib><creatorcontrib>Chen, Tsung-Chih</creatorcontrib><creatorcontrib>Yeh, Shih-Peng</creatorcontrib><creatorcontrib>Chen, Yeu-Chin</creatorcontrib><creatorcontrib>Huang, Cih-En</creatorcontrib><creatorcontrib>Chiang, I-Ju</creatorcontrib><creatorcontrib>Chung, Chu-Han</creatorcontrib><creatorcontrib>Lee, Yee-Ming</creatorcontrib><creatorcontrib>Ku, Fan-Chen</creatorcontrib><creatorcontrib>Chang, Cheng-Shyong</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kuo, Ming-Chung</au><au>Lin, Chien-Chin</au><au>Lin, Hsuan-Yu</au><au>Gau, Jyh-Pyng</au><au>Wang, Ming-Chung</au><au>Chang, Ming-Chih</au><au>Chen, Tsung-Chih</au><au>Yeh, Shih-Peng</au><au>Chen, Yeu-Chin</au><au>Huang, Cih-En</au><au>Chiang, I-Ju</au><au>Chung, Chu-Han</au><au>Lee, Yee-Ming</au><au>Ku, Fan-Chen</au><au>Chang, Cheng-Shyong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and Effectiveness of Ruxolitinib in Real-World Patients with Myelofibrosis: A 2-Year Observational Study from Taiwan</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>9709</spage><epage>9710</epage><pages>9709-9710</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-156146</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2022-11, Vol.140 (Supplement 1), p.9709-9710
issn 0006-4971
1528-0020
language eng
recordid cdi_crossref_primary_10_1182_blood_2022_156146
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title Safety and Effectiveness of Ruxolitinib in Real-World Patients with Myelofibrosis: A 2-Year Observational Study from Taiwan
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T09%3A02%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20Effectiveness%20of%20Ruxolitinib%20in%20Real-World%20Patients%20with%20Myelofibrosis:%20A%202-Year%20Observational%20Study%20from%20Taiwan&rft.jtitle=Blood&rft.au=Kuo,%20Ming-Chung&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=9709&rft.epage=9710&rft.pages=9709-9710&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-156146&rft_dat=%3Celsevier_cross%3ES0006497122059249%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497122059249&rfr_iscdi=true